Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: Comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine

International Journal of Radiation Oncology Biology Physics

Volumn 67, Issue 3, 2007, Pages 651-659

  Münter, Marc W ^a,b   Hoffner, Simone ^a,c   Hof, Holger ^a   Herfarth, Klaus K ^a   Haberkorn, Uwe ^a   Rudat, Volker ^d   Huber, Peter ^b   Debus, Jürgen ^a   Karger, Christian P ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c St Vincentius Kliniken Karlsruhe   (Germany)

^d ST JOSEF HOSPITAL   (Germany)

Author keywords

Amifostine; Head and neck tumors; Intensity modulated radiotherapy; Quantitative scintigraphy; Xerostomia

Indexed keywords

BIOLOGICAL ORGANS; BIOMEDICAL ENGINEERING; DOSIMETRY; PATIENT TREATMENT; RADIOTHERAPY;

AMIFOSTINE; HEAD-AND-NECK TUMORS; INTENSITY-MODULATED RADIOTHERAPY; QUANTITATIVE SCINTIGRAPHY; SALIVARY GLAND; XEROSTOMIA;

TUMORS;

AMIFOSTINE; PERTECHNETIC ACID TC 99M;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; EVALUATION; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; PAROTID GLAND; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE; SALIVARY GLAND; SALIVARY GLAND FUNCTION; SUBMANDIBULAR GLAND;

ADULT; AGED; AMIFOSTINE; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PAROTID GLAND; RADIATION-PROTECTIVE AGENTS; RADIOPHARMACEUTICALS; RADIOTHERAPY, INTENSITY-MODULATED; SALIVARY GLANDS; SALIVATION; SODIUM PERTECHNETATE TC 99M; XEROSTOMIA;

EID: 33846782839     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.09.035     Document Type: Article

References (30)

1. Huguenin P.U., Taussky D., Moe K., et al. Quality of life in patients cured from a carcinoma of the head-and-neck by radiotherapy: The importance of the target volume. Int J Radiat Oncol Biol Phys 45 (1999) 47-52
2. Gornitsky M., Shenouda G., Sultanem K., et al. Double-blind randomized, placebo-controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head-and-neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98 (2004) 45-52
3. Grotz K.A., Henneicke-von Zepelin H.H., Kohnen R., et al. [Prospective double-blind study of prophylaxis of radioxerostomia with Coumarin/Troxerutine in patients with head-and-neck cancer]. Strahlenther Onkol 175 (1999) 397-404
4. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head-and-neck cancer. J Clin Oncol 18 (2000) 3339-3345
5. Chao K.S. Protection of salivary function by intensity-modulated radiation therapy in patients with head-and-neck cancer. Semin Radiat Oncol 12 (2002) 20-25
6. Chao K.S., Deasy J.O., Markman J., et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: Initial results. Int J Radiat Oncol Biol Phys 49 (2001) 907-916
7. Eisbruch A., Kim H.M., Terrell J.E., et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 50 (2001) 695-704
8. Munter M.W., Karger C.P., Hoffner S.G., et al. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. Int J Radiat Oncol Biol Phys 58 (2004) 175-184
9. Munter M.W., Debus J., Hof H., et al. Inverse treatment planning and stereotactic intensity-modulated radiation therapy (IMRT) of the tumor and lymph node levels for nasopharyngeal carcinomas. Description of treatment technique, plan comparison, and case study. Strahlenther Onkol 178 (2002) 517-523
10. Coppes R.P., Vissink A., Zeilstra L.J., et al. Muscarinic receptor stimulation increases tolerance of rat salivary gland function to radiation damage. Int J Radiat Biol 72 (1997) 615-625
11. Peter B., Van Waarde M.A., Vissink A., et al. The role of secretory granules in radiation-induced dysfunction of rat salivary glands. Radiat Res 141 (1995) 176-182
12. Vissink A., s-Gravenmade E.J., Ligeon E.E., et al. A functional and chemical study of radiation effects on rat parotid and submandibular/sublingual glands. Radiat Res 124 (1990) 259-265
13. Coppes R.P., Vissink A., and Konings A.W. Comparison of radiosensitivity of rat parotid and submandibular glands after different radiation schedules. Radiother Oncol 63 (2002) 321-328
14. StatSoft I. STATISTICA für Windows (Software-System für Datenanalyse) Version 6. www.statsoft.com. 2004
15. Karger C.P., and Hartmann G.H. Determination of tolerance dose uncertainties and optimal design of dose response experiments with small animal numbers. Strahlenther Onkol 177 (2001) 37-42
16. Wasserman T.H., Brizel D.M., Henke M., et al. Influence of intravenous Amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and-neck cancer: 2-Year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys 63 (2005) 985-990
17. Buentzel J., Micke O., Adamietz I.A., et al. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: A randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 64 (2006) 684-691
18. Shaw L.M., Bonner H.S., Schuchter L., et al. Pharmacokinetics of amifostine: Effects of dose and method of administration. Semin Oncol 26 (1999) 34-36
19. Vacha P., Fehlauer F., Mahlmann B., et al. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head-and-neck cancer. Is there evidence for radioprotection?. Strahlenther Onkol 179 (2003) 385-389
20. Antonadou D., Pepelassi M., Synodinou M., et al. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 52 (2002) 739-747
21. Roesink J.M., Moerland M.A., Hoekstra A., et al. Scintigraphic assessment of early and late parotid gland function after radiotherapy for head-and-neck cancer: A prospective study of dose-volume response relationships. Int J Radiat Oncol Biol Phys 58 (2004) 1451-1460
22. Kohn W.G., Ship J.A., Atkinson J.C., et al. Salivary gland 99mTc-scintigraphy: A grading scale and correlation with major salivary gland flow rates. J Oral Pathol Med 21 (1992) 70-74
23. Kuhnt T., Jirsak N., Muller A.C., et al. [Quantitative and qualitative investigations of salivary gland function in dependence on irradiation dose and volume for reduction of xerostomia in patients with head-and-neck cancer]. Strahlenther Onkol 181 (2005) 520-528
24. Rades D., Fehlauer F., Bajrovic A., et al. Serious adverse effects of amifostine during radiotherapy in head-and-neck cancer patients. Radiother Oncol 70 (2004) 261-264
25. Kwong D.L., Pow E.H., Sham J.S., et al. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: A prospective study on disease control and preservation of salivary function. Cancer 101 (2004) 1584-1593
26. Chao K.S., Ozyigit G., Blanco A.I., et al. Intensity-modulated radiation therapy for oropharyngeal carcinoma: Impact of tumor volume. Int J Radiat Oncol Biol Phys 59 (2004) 43-50
27. Wolden S.L., Chen W.C., Pfister D.G., et al. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: Update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 64 (2006) 57-62
28. Saarilahti K., Kouri M., Collan J., et al. Intensity modulated radiotherapy for head-and-neck cancer: Evidence for preserved salivary gland function. Radiother Oncol 74 (2005) 251-258
29. Eisbruch A., Ten Haken R.K., Kim H.M., et al. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 45 (1999) 577-587
30. Saarilahti K., Kouri M., Collan J., et al. Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head-and-neck cancer. Radiother Oncol 78 (2006) 270-275